Bristol comes out swinging at Lilly clot drug
NEW YORK (Reuters) - Bristol-Myers Squibb Co, which sells leading blood clot preventer Plavix, on Thursday dismissed Eli Lilly and Co's rival Effient drug as a "niche" product that has harmed or failed to help three groups of patients in a big study.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=6tQlaY" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=6tQlaY)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=yahnXJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=yahnXJ) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=BiMBtj" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=BiMBtj) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=S7yKuj" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=S7yKuj)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/345018132" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/345018132/idUSN2449295120080724